- Home
- MYO vs BCAB Comparison
MYO vs BCAB Comparison
Compare MYO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- BCAB
- Stock Information
- Founded
- MYO 2004
- BCAB 2007
- Country
- MYO United States
- BCAB United States
- Employees
- MYO N/A
- BCAB N/A
- Industry
- MYO Industrial Specialties
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- MYO Health Care
- BCAB Health Care
- Exchange
- MYO Nasdaq
- BCAB Nasdaq
- Market Cap
- MYO 36.5M
- BCAB 40.5M
- IPO Year
- MYO 2017
- BCAB 2020
- Fundamental
- Price
- MYO $0.83
- BCAB $0.68
- Analyst Decision
- MYO Strong Buy
- BCAB Hold
- Analyst Count
- MYO 3
- BCAB 3
- Target Price
- MYO $7.83
- BCAB $1.00
- AVG Volume (30 Days)
- MYO 1.2M
- BCAB 1.1M
- Earning Date
- MYO 11-10-2025
- BCAB 11-13-2025
- Dividend Yield
- MYO N/A
- BCAB N/A
- EPS Growth
- MYO N/A
- BCAB N/A
- EPS
- MYO N/A
- BCAB N/A
- Revenue
- MYO $40,760,091.00
- BCAB $11,000,000.00
- Revenue This Year
- MYO $24.69
- BCAB N/A
- Revenue Next Year
- MYO $20.91
- BCAB N/A
- P/E Ratio
- MYO N/A
- BCAB N/A
- Revenue Growth
- MYO 93.08
- BCAB N/A
- 52 Week Low
- MYO $0.79
- BCAB $0.24
- 52 Week High
- MYO $7.17
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- MYO 36.62
- BCAB 48.77
- Support Level
- MYO $0.81
- BCAB $0.60
- Resistance Level
- MYO $0.88
- BCAB $0.69
- Average True Range (ATR)
- MYO 0.07
- BCAB 0.07
- MACD
- MYO -0.02
- BCAB -0.01
- Stochastic Oscillator
- MYO 13.10
- BCAB 42.45
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.